Skip to main content

ATB Cormark Capital Markets Reaffirms Their Hold Rating on Tilray (TLRY)

Tipranks - Tipranks - Wed Mar 4, 7:34AM CST

In a report released today, Frederico Gomes from ATB Cormark Capital Markets maintained a Hold rating on Tilray, with a price target of $9.50.

Claim 70% Off TipRanks Premium

Gomes covers the Healthcare sector, focusing on stocks such as Tilray, Organigram Global, and Canopy Growth. According to TipRanks, Gomes has an average return of -5.4% and a 52.78% success rate on recommended stocks.

In addition to ATB Cormark Capital Markets, Tilray also received a Hold from TipRanks – OpenAI’s OpenAI Drug Manufacturers – Specialty and Generic in a report issued today. However, on March 1, TipRanks – Anthropic reiterated a Sell rating on Tilray (NASDAQ: TLRY).

See today’s best-performing stocks on TipRanks >>

Based on Tilray’s latest earnings release for the quarter ending November 30, the company reported a quarterly revenue of $303.85 million and a GAAP net loss of $62.77 million. In comparison, last year the company earned a revenue of $295.06 million and had a GAAP net loss of $119.37 million

Read More on TLRY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).